A Study of LY3050258 in Healthy Participants

Summary

The main purpose of this study is to evaluate the safety and how well the body will handle a single dose of increasing strength of study drug LY3050258. Each participant will receive LY3050258 or placebo once, in each of 2 dosing periods. At least 7 days will pass between doses. This study will last approximately 45 days for each participant. Screening is required within 28 days before the start of the study.

Timeline

Start

2013-08

Primary completion

2013-12

Completion

2013-12

Drugs

Indications

No indication recorded.